Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary

Inclusion Criteria: * Age 18-80 * KPS ≥ 60 * At least one recurrent or progressive brain metastasis (es) from any solid primary tumor that is visible on MRI as assessed by the patient's treating physician. * Recurrence may occur after any treatment: recurrence after whole-brain radiation, stereotactic radiosurgery, surgical resection, systemic chemotherapy are all acceptable. * There is no limit on the number of brain metastases. * Surgical resection or SRS to other recurrent lesions in the same patient are acceptable, provided one recurrent lesion remains untreated. * Systemic disease must be well-controlled or NED in the opinion of the patient's primary oncologist. Exclusion Criteria: * Inability to get brain MRI +/- contrast * Progressive systemic disease * Known leptomeningeal metastases * Primary Brain tumor * Active Intracranial Hemorrhage * Surgery less than two weeks before enrollment * GI hemorrhage (active or in recent 6 months) * Concurrent anti-platelet therapy * Concurrent anti-coagulation therapy * Active bleeding diathesis * Platelet count ≤ 70,000/mm3 * International normalized ratio (INR) \> 1.6 and a Partial Thromboplastin Time (PTT) \> 40 seconds * Serum Creatinine \>2 mg/dL OR CrCL \<30ml/min * AST or ALT \> 200 U/L * Hemoglobin \<8 g/dL * Allergy to meclofenamate or other NSAID * Inability to tolerate PO dosing * Steroid dose increased in the most recent two weeks. * Pregnancy * Cardiac Arrhythmia requiring medical management and/or pacemaker. * Known congestive heart failure requiring medical management